A mom “didn’t feel taken seriously” even as her symptoms worsened. Then tests found a rare disease.

A Mom Felt Overlooked as Her Symptoms Escalated, Until Rare Diagnosis Was Unveiled

A mom didn t feel taken - Michelle Williams’ journey to understanding her health began with something she initially dismissed—elevated blood pressure. With two young children, the ongoing pandemic, and a farmhouse renovation underway, she attributed her stress levels to the chaotic lifestyle. Her physician suggested minor adjustments to her routine, like eating healthier or exercising more, without expressing concern. As the months passed, however, her condition worsened in ways that grew harder to ignore. Her feet swelled so severely that she needed larger shoes, and constant trips to the bathroom left her exhausted and sleep-deprived. Despite these changes, her blood pressure continued to climb, accompanied by swelling in her ankles and legs. It wasn’t until a referral to a kidney specialist in June 2023 that the situation took a critical turn.

The Moment of Doubt

Williams described her encounter with the kidney specialist as disheartening. The physician assistant she met that day appeared uninterested in reviewing the medical records she had prepared and brought with her. “They just told me to work on lowering my blood pressure,” she recalled. “No one seemed to care about why it was so high.” This lack of attention left her feeling frustrated and anxious. “I got to my car, and I was just depressed,” she said. “Something was wrong, and I didn’t feel like I had six months to wait for answers.”

Her resolve to seek further care led her to the Cleveland Clinic, where her father-in-law had previously undergone a kidney transplant. There, she shared her medical history and a heartfelt letter pleading for assistance. “Please help me, something’s wrong,” she wrote, urging the team to take her symptoms seriously. The clinic responded by scheduling her for two full days of appointments, during which she underwent a series of tests. As she and her husband prepared to return home, a phone call from the nephrologist changed everything. The doctor, reviewing her lab results, now expressed urgency. “We needed to biopsy her bone marrow and kidneys,” Williams said, highlighting the shift from indifference to concern.

Uncovering the Diagnosis

Williams and her husband immediately drove back to the clinic for the biopsies. Over the next 24 hours, she endured extensive procedures to rule out other potential causes. The findings revealed abnormalities in her urine and bone marrow, ultimately leading to a diagnosis of multiple myeloma—a type of blood cancer that can damage the kidneys. For nearly six months, she underwent chemotherapy and immunotherapy, yet her symptoms persisted, raising questions about the effectiveness of the treatment. “It really got me thinking: If we’re addressing the root cause and she’s not improving, what else are we missing?” Dr. Jagmeet Dhingra, a nephrologist at the Cleveland Clinic, reflected on the case. “We kept searching because her response wasn’t what we expected.”

The breakthrough came after additional tests showed her bone marrow was healthy, but complex immune deposits were accumulating in her kidneys. This led to the identification of a rare condition: IC-MPGN. Dr. Carla Nester, a nephrologist and researcher at the University of Iowa, explained that this disease is one of the least common kidney disorders. “Only about one to four people per million are diagnosed with it,” she said. IC-MPGN, or immune complex-mediated proliferative glomerulonephritis, is linked to the immune system and often presents with symptoms like swelling and fatigue, which Williams experienced.

At the time of her diagnosis, there were no targeted treatments for IC-MPGN. Standard care involved steroids, immunosuppressants, and even chemotherapy, which provided some relief but did not halt the disease’s progression. Nester noted that patients were typically given a prognosis of approximately 10 years before reaching end-stage kidney disease. Even a kidney transplant could only delay the inevitable, as the underlying condition remained untreated. “We were not fixing the problem,” Nester said. “It was a horrible prognosis, frankly.”

A New Hope in Research

Williams’ frustration with traditional treatments led her to explore alternative options. For months, she felt trapped by the medications she was prescribed, which either failed to alleviate her symptoms or caused side effects. “I was just in a fog,” she remembered. “It felt like I had to make the best of a limited set of choices.” Her turning point arrived in November 2024 when Dhingra informed her about a clinical trial. The opportunity to participate in new research gave her a sense of control and hope.

The trial, which focused on experimental therapies for immune-related kidney diseases, became a lifeline for Williams. She described the experience as transformative, emphasizing how it allowed her to feel part of a larger effort to combat her condition. “It was like a light came on,” she said. “I wasn’t just a patient anymore; I was a participant in something groundbreaking.” The study aimed to understand the role of immune complexes in kidney damage and tested innovative approaches to reduce their impact. For Williams, it was a chance to see if the medical community could finally provide the answers she had long sought.

IC-MPGN remains a challenging diagnosis due to its rarity and the difficulty in recognizing its symptoms early. Nester stressed that most patients notice signs only when the disease has progressed significantly. “They often come in with a substantial burden of symptoms before being diagnosed,” she said. This delay can lead to complications, as the condition affects the kidneys’ ability to filter waste and regulate fluids. For Williams, the journey from dismissal to diagnosis underscored the importance of persistence and the need for more awareness about rare diseases.

Her story has since inspired others facing similar challenges. “It’s a reminder that even when symptoms seem minor, they can be the first signs of something serious,” Dhingra noted. He emphasized that early intervention is crucial for better outcomes, especially in conditions like IC-MPGN. “We need to listen to patients’ concerns and not assume they’re just stress-related,” he added. For Williams, the experience of being overlooked initially has become a powerful advocacy message. She now works to raise awareness about the importance of thorough medical evaluations, particularly for those with persistent or worsening symptoms.

As of now, the clinical trial has shown promising results, offering a glimmer of hope for patients with IC-MPGN. Williams’ participation not only improved her own health but also contributed to advancements in treating this rare condition. Her story highlights the critical role of patient advocacy and the potential for research to transform even the most daunting diagnoses. “I didn’t feel taken seriously at first,” she said, “but now I’m proof that persistence can lead to answers.”